Trial Profile

Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cagrilintide (Primary) ; Cagrilintide/semaglutide (Primary) ; NNC0194 0499 (Primary) ; Semaglutide (Primary)
Indications Alcohol-related disorders
Focus Therapeutic Use
Sponsors Novo Nordisk

18 May 2025 Status changed from recruiting to active, no longer recruiting.
15 Apr 2025 Planned End Date changed from 16 Jan 2026 to 1 Jan 2026.
15 Apr 2025 Planned primary completion date changed from 28 Nov 2025 to 13 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com